Is Male Sex A Prognostic Factor in Papillary Thyroid Cancer?

Alekssandra Gajowiec 1,*, Anna Chromik 1, Kinga Furga 1, Alicja Skuza 1, Danuta Gaśior-Perczak 2,3, Agnieszka Walczyk 2,3, Iwona Pałyga 2,3, Tomasz Trybek 2,3,1, Klaudia Gąsior-Kowalska 2,3, Artur Kuchareczko 3, Agnieszka Suligowska 3, Jarosław Jaskulski 2, Paweł Orłowski 2, Magdalena Chrapek 4, Stanisław Goźdz 2,5 and Aldona Kowalska 2,3

Abstract: Identifying risk factors is crucial for predicting papillary thyroid cancer (PTC) with severe course, which causes a clinical problem. The purpose of this study was to assess whether male sex can be such a predictive factor and to verify whether including it as a predictive factor of high initial risk of recurrence/persistence would help to enhance the value of the American Thyroid Association initial risk stratification system (ATA). We retrospectively analyzed 1547 PTC patients (1358 females and 189 males), treated from 1986 to 2018. The relationship between sex and clinicopathological features, response to therapy, and disease status was assessed. Men with PTC showed some adverse clinicopathological features more often than women, including angioinvasion, lymph node metastases, and tumor size > 40 mm. There were sex-related disparities with respect to response to initial therapy and final follow-up. Male sex is associated with some unfavorable clinicopathological features of PTC, which may affect response to initial therapy or final disease status. In our study, modification of the ATA system by including male sex as a risk factor does not enhance its value. Thus, further studies are needed to assess whether males require treatment modalities or oncological follow-up protocols that are different from those of females.

Keywords: papillary thyroid cancer; male sex; response to therapy; risk stratification

1. Introduction

Thyroid carcinoma (TC) is the most common malignancy of the endocrine system. According to the World Health Organization database, 567,233 new cases of TC were reported in 2018: 130,889 cases in men and 436,344 in women [1]. Exposure to radiation, low iodine intake, genetics, obesity, and smoking are associated with an increased risk of developing TC [2,3]. Well-differentiated TC (DTC), which originates from thyroid follicular epithelial cells, is the most common type of TC, accounting for approximately 90% of cases [4]. The prevalence of DTC, particularly papillary thyroid cancer, continues to rise worldwide.

The sharp increase in the incidence of TC (mostly small cancers) over the past three decades is mainly due to the development of widely available and sensitive detection methods such as thyroid ultrasound and to increased availability of ultrasound-guided
fine-needle aspiration [4]. Furthermore, we observe an increase in the incidence of larger thyroid cancers due to exposure to radiation, low iodine intake, genetics, obesity, and smoking [5,6]. PTC, the most common type of DTC, is a relatively benign tumor with a favorable prognosis. However, there is a disparity in morbidity between women and men. Previous studies report that the incidence of thyroid cancer is 3–5-fold higher in women [7,8]; however, reports suggest that the disease is more aggressive in men [9]. Male sex is associated with a worse prognosis for PTC, especially more advanced disease, and aggressive subtypes [9,10]. Men tend to be diagnosed at an older age and have shorter disease-free survival [10,11]. In females, the age-specific incidence rate rises sharply at the beginning of the reproductive years, peaking at 40–49 years, while in men, the peak is at 60–69 years. The incidence rates equalize by 85 years. However, the link between sex and presentation of DTC is ambiguous.

The aim of the present study was to analyze the effect of male sex on occurrence of PTC with unfavorable clinicopathological features and to examine whether men show a different response to therapy. Another objective was to verify whether male sex should be considered as a risk factor for recurrent/persistent disease according to the American Thyroid Association (ATA) initial risk stratification system which would help to enhance the accuracy of this system.

2. Experimental Section

The medical records of 1900 Caucasian patients with PTC, all of whom underwent total thyroidectomy or lobectomy during 1986–2018, were examined retrospectively. The following data were obtained: type of cancer, sex, prognostic clinicopathological features (i.e., age at diagnosis, tumor diameter, multifocality, lymph node metastases, angioinvasion, extrathyroidal extension, and distant metastases), response to initial therapy, and clinical outcome (i.e., no evidence of disease (NED), recurrence, persistent disease, or death). Patients with follow-up less than 12 months, lacking complete data, and those with a non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) were excluded. Patients who were lost to follow-up for reasons other than death were also excluded. The data of 25 patients who underwent total thyroidectomy between 1986 and 1999 were obtained from other centers. The study ultimately included 1547 patients.

All patients included in the study underwent surgery as the primary treatment: lobectomy, total thyroidectomy, or total thyroidectomy with central compartment lymphadenectomy. The extent of the surgery and surgical procedures has been described by us previously [12].

Postoperative TNM staging of all included patients was re-classified according to the most recent 8th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) TNM staging system and the American Thyroid Association (ATA) modified initial risk stratification system [13]

Response to therapy was assessed 1 year after initial treatment. Patients treated with radioiodine (131I) were assessed for their response to initial therapy (surgery plus 131I) using the criteria proposed by Tuttle et al. [14], which were accepted by the ATA [15]. The procedures performed during the follow-up and assessment of treatment responses have been described previously [16].

The response to initial therapy (either total thyroidectomy or lobectomy) of patients not treated with radioiodine was assessed using criteria proposed by Momesso and Tuttle [17]. The procedures used to monitor disease course from the end of surgical treatment to evaluation of response were described previously [18]. Treatment response was classified as excellent, indeterminate, biochemically incomplete, or structurally incomplete.

Information about recurrence was obtained from medical records. Recurrence was defined as biochemical or structural disease after a period of NED (at least 12 months after initial therapy).

The clinical status of the patient was assessed based on medical records and by applying the latest ATA guidelines. Patients were then assigned to one of four groups:
NED, persistent disease, death from cancer, and death from other causes. The follow-up results were finally concluded on 31 May 2020.

The study plan was accepted by the Bioethics Committee at Jan Kochanowski University in Kielce, Poland (Number-7/2020). Written informed consent was not required because the data were obtained retrospectively.

Continuous data are expressed as the median, lower (Q1) and upper (Q3) quartiles, and range (minimum–maximum). Categorical data are expressed as numbers and percentages. Group comparisons were performed using the Chi-squared or Fisher’s exact test (categorical variables), the t-test (continuous, normally distributed variables) or the Mann–Whitney test (continuous, non-normally distributed variables). The normality of data was checked using the Shapiro–Wilk test.

Univariate and multivariate logistic regression models were used to analyze excellent responses to initial therapy and NED during follow-up; in these models, odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated. Statistical tests were two-tailed, and a p-value of <0.05 was considered significant. All statistical analyses were performed using the R software package version 3.6.1 (R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/, accessed on 13 May 2021).

3. Results

3.1. Characteristics of the Study Group

The database included 1547 cases (1358 females (87.8%) and 189 males (12.2%); median age at diagnosis, 50 years; range, 15–85 years). Of these, 64.0% (990/1547) were younger than 55 years. The most frequent cancer histological variant was classic variant (71.8%; 1111/1547). Angioinvasion was present in 4.7% of patients (72/1547) and multifocality in 26.1% (404/1547). In 3.0% (46/1547) of cases, tumor diameter was >40 mm (median tumor size, 8.0 mm; range, 0.3–110.0 mm). Extrathyroidal extension (ETE) occurred in 19.2% of cases: minor ETE in 17.6% (272/1547) and gross ETE in 1.6% (25/1547). Lymph node metastases were identified in 14.5% of cases (225/1547); 1.0% (15/1547) of patients developed distant metastases (M1). Only 5.3% (81/1547) of cases had disease stage >I according to the AJCC TNM Staging System for Differentiated and Anaplastic Thyroid Cancer (8th Edition) criteria. The ATA initial risk stratification system rated the majority (68.2%, 1055/1547) as low risk of recurrence/persistence. Radioactive iodine therapy was applied in 1054/1547 (68.1%) patients. The characteristics of the study group are presented in Table 1.

| Table 1. Characteristics of the study group. |
|---------------------------------------------|
| Sex, n (%)                                   |
| Female                                      | 1358 (87.8%) |
| Male                                        | 189 (12.2%)  |
| Median age, years (Q1–Q3; range)            | 50.0 (39.0, 59.0; 15.0–85.0) |
| Age at diagnosis, ≥55 years, n (%)          | 557 (36.0%)  |
| Median tumor size, mm (Q1–Q3; range)        | 8.0 (5.0–14.0; 0.3–110.0) |
| Tumor diameter, >40 mm, n (%)               | 46 (3.0%)    |
| Papillary cancer histologic variant, n (%)  |
| Classic                                     | 1111 (71.8%) |
| Follicular                                   | 363 (23.5%)  |
| Oxyphilic                                    | 13 (0.8%)    |
| Diffuse sclerosing                          | 9 (0.6%)     |
| Tall cell                                   | 4 (0.3%)     |
| Other                                       | 47 (3.0%)    |
Table 1. Cont.

|                                | Total (n = 1547) |
|--------------------------------|------------------|
| Multifocality, n (%)           |                  |
| No                             | 1143 (73.9%)     |
| Yes                            | 404 (26.1%)      |
| Extrathyroidal extension, n (%)|                  |
| No                             | 1250 (80.8%)     |
| Minor                          | 272 (17.6%)      |
| Gross                          | 25 (1.6%)        |
| Angioinvasion, n (%)           |                  |
| No                             | 1475 (95.3%)     |
| Yes                            | 72 (4.7%)        |
| Tumor stage, n (%)             |                  |
| pT1a                           | 980 (63.3%)      |
| pT1b                           | 349 (22.6%)      |
| pT2                            | 152 (9.8%)       |
| pT3a                           | 42 (2.7%)        |
| pT3b                           | 17 (1.1%)        |
| pT4a                           | 6 (0.4%)         |
| pT4b                           | 1 (0.1%)         |
| Nodal metastases, n (%)        |                  |
| N0a                            | 801 (51.8%)      |
| N0b                            | 521 (33.7%)      |
| N1a                            | 124 (8.0%)       |
| N1b                            | 101 (6.5%)       |
| Distant metastases, n (%)      |                  |
| M0                             | 1532 (99.0%)     |
| M1                             | 15 (1.0%)        |
| TNM stage, n (%)               |                  |
| I                              | 1466 (94.8%)     |
| II                             | 71 (4.6%)        |
| III                            | 2 (0.1%)         |
| IVa                            | 1 (0.1%)         |
| IVb                            | 7 (0.5%)         |
| ATA initial risk, n (%)        |                  |
| Low                            | 1055 (68.2%)     |
| Intermediate                   | 427 (27.6%)      |
| High                           | 65 (4.2%)        |
| Radioactive iodine therapy     |                  |
| No                             | 493 (31.9%)      |
| Yes                            | 1054 (68.1%)     |
| Therapy 131I > 1               |                  |
| No                             | 1371 (88.6%)     |
| Yes                            | 176 (11.4%)      |

TNM, tumor node metastases; ATA, American Thyroid Association; N0a, one or more cytologically or histologically confirmed benign lymph node; N0b, no radiologic or clinical evidence of locoregional lymph node metastases; N1a-b, metastases to regional lymph nodes.

3.2. Response to Initial Therapy, Recurrence, and Final Clinical Status

3.2.1. Response to Initial Therapy

Response to treatment was assessed in all 1547 patients. The following results were obtained: excellent response to initial therapy was observed in 1259 patients (81.4%), and an indeterminate response was observed in 234 (15.1%). Twenty-two patients (1.4%) achieved a biochemically incomplete response, and 32 (2.1%) achieved a structurally incomplete response.

3.2.2. Recurrence

The rate of recurrence after an excellent response to initial therapy was 19/1259 (1.5%).
3.2.3. Final Clinical Status

At final follow-up, NED was found in 1423/1547 cases (92.0%). Non-NED was observed in 124/1547 (8.0%) patients (indeterminate, 102 (6.6%); biochemically persistent, 12 (0.8%); and structurally persistent, 10 (0.6%)). The median follow-up time was 6.0 years (range, 1.0–34.0 years). Overall, sixteen patients died (16/1547; 1.0%). There were no cancer-related deaths. The results are presented in Table 2.

Table 2. Response to initial therapy, recurrence, and final clinical status.

| Response to Initial Therapy, n (%) | Total (n = 1547) |
|-----------------------------------|------------------|
| Excellent                         | 1259 (81.4%)     |
| Indeterminate                     | 234 (15.1%)      |
| Biochemical incomplete            | 22 (1.4%)        |
| Structural incomplete             | 32 (2.1%)        |

| Recurrence after an Excellent Response to Initial Therapy, n (%) | Total (n = 1259) |
|-----------------------------------------------------------------|------------------|
| No                                                              | 1240 (98.5%)     |
| Yes                                                             | 19 (1.5%)        |

| Final Follow-Up, n (%) | Total (n = 1547) |
|-----------------------|------------------|
| NED                   | 1423 (92.0%)     |
| Indeterminate         | 102 (6.6%)       |
| Biochemically persistent disease | 12 (0.8%)   |
| Structurally persistent disease | 10 (0.6%)   |

| Death, n (%) | Total (n = 1547) |
|--------------|------------------|
| No           | 1531 (99.0%)     |
| Yes (TC-unrelated) | 16 (1.0%) |

| Median Follow-Up Time, Years (Range) | 6.0 (1.0–34.0) |

NED, no evidence of disease; TC, thyroid cancer.

3.3. Baseline Characteristics According to Sex

A comparison of baseline tumor characteristics between the sexes is presented in Table 3. The research group comprised 1358 women and 189 men. In this study, PTC was more than seven times as common in women as in men. The median age was 50 years (range, 15–85) for women and 51 years (range, 20–80) for men. Median tumor size in patients did not differ according to sex and was 8.0 mm (range, 0.3–80.0 mm for women and 0.3–110.0 mm for men). Significantly fewer females had tumors > 40 mm: 2.4% (32/1358) vs. 7.4% (14/189); p = 0.0001. The most frequent papillary cancer histologic variant in both sexes was classic (71.1% of women, 76.7% of men). The incidence of angioinvasion differed according to sex: 7.9% (15/189) of males and 4.2% (57/1358) of females (p = 0.0222). There was a significant difference in occurrence of regional lymph node metastases in males and females (Table 3). The TNM classification system classified nodal metastases as 1a or 1b in 23.8% (45/189) of males and in 13.2% (180/1358) of females (p < 0.0001). There was a significant sex-related difference in disease stage, as assessed by the AJCC TNM Staging System for Differentiated and Anaplastic Thyroid Cancer (8th Edition) criteria. Men were more likely to have disease stage > I. Only 0.4% (5/1358) of women (compared with 1.6% (3/189) of men) were diagnosed with the most advanced stage of cancer (IVa and IVb; p = 0.0005). According to the ATA initial risk of recurrence and persistence stratification system significantly more men (7.9%, 15/189) than women (3.7%, 50/1358) were in the high-risk group (p = 0.0054). Among women, 67.4% (915/1358) were treated with radioiodine, while among men 73.5% (139/189); significantly more men than women received 131I treatment more than once (10.8% of women, 15.9% of men, p = 0.0377).

3.4. Response to Initial Therapy, Recurrence, and Final Clinical Status According to Sex

3.4.1. Response to Initial Therapy

Univariate analysis identified significant differences between the sexes with respect to excellent and non-excellent responses to initial therapy. Results were confirmed by multivariate analysis, meaning that male sex is an independent risk factor for a worse
response to therapy. Other risk factors such as angioinvasion and nodal metastases may affect the results of univariate analysis. In patients with PTC, 82.8% (1125/1358) of females versus 70.9% (134/189) of males showed an excellent response to initial therapy. In this group, a non-excellent response was observed in 17.2% (233/1358) of females and 29.1% (55/189) of males ($p < 0.0001$). The results are presented in Table 4.

Table 3. Baseline characteristics according to sex.

|                          | Female ($n = 1358$) | Male ($n = 189$) | Total ($n = 1547$) | $p$-Value |
|--------------------------|---------------------|------------------|--------------------|-----------|
| Median age, years (Q1–Q3; range) | 50.0 (39.0–58.8; 15–85) | 51.0 (41.0–60.0; 20–80) | 50.0 (39.0–59.0; 15–85) | 0.1297    |
| Age at diagnosis, ≥55 years, $n$ (%) | 481 (35.4%) | 76 (40.2%) | 557 (36.0%) | 0.1985    |
| Median tumor size, mm (Q1–Q3; range) | 8.0 (5.0–13.0; 0.3–80.0) | 8.0 (5.0–23.0; 0.3–110) | 8.0 (5.0–14.0; 0.3–110) | 0.0776    |
| Tumor diameter, >40 mm, $n$ (%) | 32 (2.4%) | 14 (7.4%) | 46 (3.0%) | 0.0001    |
| Classical | 966 (71.1%) | 145 (76.7%) | 1111 (71.8%) |          |
| Follicular | 325 (23.9%) | 38 (20.1%) | 363 (23.5%) |          |
| Oxyphilic | 11 (0.8%) | 2 (1.1%) | 13 (0.8%) |          |
| Diffuse sclerosing | 9 (0.7%) | 0 (0.0%) | 9 (0.6%) |          |
| Tall cell | 4 (0.3%) | 0 (0.0%) | 4 (0.3%) |          |
| Other | 43 (3.2%) | 4 (2.1%) | 47 (3.0%) | 0.623     |
| Multifocality, $n$ (%) |                          |                  |                    |           |
| No | 1010 (74.4%) | 133 (70.4%) | 1143 (73.9%) |          |
| Yes | 348 (25.6%) | 56 (29.6%) | 404 (26.1%) | 0.2404    |
| Extrathyroidal extension, $n$ (%) |                          |                  |                    |           |
| No | 1107 (81.5%) | 143 (75.7%) | 1250 (80.8%) |          |
| Minor | 230 (16.9%) | 42 (22.2%) | 272 (17.6%) | 0.1403    |
| Gross | 21 (1.5%) | 4 (2.1%) | 25 (1.6%) |          |
| Angioinvasion, $n$ (%) |                          |                  |                    |           |
| No | 1301 (95.8%) | 174 (92.1%) | 1475 (95.3%) |          |
| Yes | 12 (0.9%) | 3 (1.6%) | 15 (1.0%) | <0.0001   |
| Tumor stage, $n$ (%) |                          |                  |                    |           |
| pT1a | 875 (64.4%) | 105 (55.6%) | 980 (63.3%) |          |
| pT1b | 315 (23.2%) | 34 (18.0%) | 349 (22.6%) |          |
| pT2 | 118 (8.7%) | 34 (18.0%) | 152 (9.8%) |          |
| pT3a | 29 (2.1%) | 13 (6.9%) | 42 (2.7%) |          |
| pT3b | 17 (1.3%) | 0 (0.0%) | 17 (1.1%) |          |
| pT4a | 4 (0.3%) | 2 (1.1%) | 6 (0.4%) |          |
| pT4b | 0 (0.0%) | 1 (0.5%) | 1 (0.1%) | <0.0001   |
| Nodal metastases, $n$ (%) |                          |                  |                    |           |
| N0a | 718 (52.9%) | 83 (43.9%) | 801 (51.8%) |          |
| N0b | 460 (33.9%) | 61 (32.3%) | 521 (33.7%) |          |
| N1a | 106 (7.8%) | 18 (9.5%) | 124 (8.0%) |          |
| N1b | 74 (5.4%) | 27 (14.3%) | 101 (6.5%) | <0.0001   |
| Distant metastases, $n$ (%) |                          |                  |                    |           |
| M0 | 1346 (99.1%) | 186 (98.4%) | 1532 (99.0%) |          |
| M1 | 12 (0.9%) | 3 (1.6%) | 15 (1.0%) | 0.4146    |
| TNM stage, $n$ (%) |                          |                  |                    |           |
Table 3. Cont.

|                | Female (n = 1358) | Male (n = 189) | Total (n = 1547) | p-Value |
|----------------|-------------------|----------------|------------------|---------|
| I              | 1298 (95.6%)      | 168 (88.9%)    | 1466 (94.8%)     |         |
| II             | 54 (4.0%)         | 17 (9.0%)      | 71 (4.6%)        |         |
| III            | 1 (0.1%)          | 1 (0.5%)       | 2 (0.1%)         |         |
| IVa            | 0 (0.0%)          | 1 (0.5%)       | 1 (0.1%)         |         |
| IVb            | 5 (0.4%)          | 2 (1.1%)       | 7 (0.5%)         | 0.0005  |
| ATA initial risk, n (%) |                  |                |                  |         |
| Low            | 941 (69.3%)       | 114 (60.3%)    | 1055 (68.2%)     |         |
| Intermediate   | 367 (27.0%)       | 60 (31.7%)     | 427 (27.6%)      |         |
| High           | 50 (3.7%)         | 15 (7.9%)      | 65 (4.2%)        | 0.0054  |
| Radioactive iodine therapy |           |                |                  |         |
| No             | 443 (32.6%)       | 50 (26.5%)     | 493 (31.9%)      |         |
| Yes            | 915 (67.4%)       | 139 (73.5%)    | 1054 (68.1%)     | 0.0883  |
| Therapy 131I > 1 |                  |                |                  |         |
| No             | 1212 (89.2%)      | 159 (84.1%)    | 1371 (88.6%)     |         |
| Yes            | 146 (10.8%)       | 30 (15.9%)     | 176 (11.4%)      | 0.0377  |

TNM, tumor node metastases; ATA, American Thyroid Association; N0a, one or more cytologically or histologically confirmed benign lymph node; N0b, no radiologic or clinical evidence of locoregional lymph node metastases; N1a-b, metastases to regional lymph nodes.

Table 4. Initial response to therapy according to sex.

| Response to Initial Therapy, n (%) | Total (n = 1547) | Female (n = 1358) | Male (n = 189) | p-Value |
|-----------------------------------|------------------|-------------------|----------------|---------|
| Excellent                         | 1259 (81.4%)     | 1125 (82.8%)      | 134 (70.9%)    |         |
| Non-excellent                     | 288 (18.6%)      | 233 (17.2%)       | 55 (29.1%)     | <0.0001 |

Univariate and multivariate analyses were performed to ascertain which clinicopathological features may affect achievement of a non-excellent response to treatment. The results are presented in Table 5.

In the study group, univariate analysis identified male sex as the single factor that increased the probability of a non-excellent response to therapy, with an OR of 1.98 (95% CI, 1.4–2.8, p = 0.0001); this was confirmed by multivariate analysis (OR 1.62; 95% CI, 1.12–2.35; p = 0.0109).

Other significant predictors that may increase the chances of achieving a response other than excellent were primary tumor size >40 mm, multifocality, nodal metastases, angioinvasion, and extrathyroidal (both minor and gross) extension. Multivariate analysis confirmed the effects of all these factors. According to univariate analysis, being in an intermediate and high-risk group also increased the chances of a non-excellent response to therapy. The “ATA initial risk” variable, along with other clinicopathological parameters, was not entered into the multivariable logistic regression model to avoid introduction of multicollinearity. Age ≥55 at diagnosis in this case was neither a positive nor a negative predictor, with an OR of 0.83 (95% CI, 0.63–1.09; p = 0.1875). Presence of distant metastases was not entered in the analysis as a predictor because no patient with distant metastases achieved excellent response.

3.4.2. Recurrence

Multivariate analysis could not have been conducted due to the fact that cancer recurrences were observed only in females (19 patients). Result of such analysis would not be reliable.

3.4.3. Final Clinical Status

At the final follow-up, 93.1% (1264/1358) of women and 84.1% (159/189) of men were classified as having NED (Table 6). We performed univariate and multivariate logistic
regression analyses to ascertain which clinicopathological features affect achievement of a non-NED diagnosis at the final follow-up. The results are presented in Table 7. Univariate analysis identified male sex as a factor that increased the probability of non-NED at the final clinical assessment. This was confirmed by multivariate analysis, with an OR of 1.96 (95% CI, 1.21–3.17; \( p = 0.0062 \)). Univariate and multivariable analyses identified nodal metastases and minor and gross ETE as predictors with a significant effect on persistence of disease. The “ATA initial risk” variable, along with other clinicopathological parameters, was not entered into the multivariable logistic regression model to avoid introduction of multicollinearity.

Table 5. Effect of clinicopathological factors on non-excellent response to initial therapy.

| Clinicopathological Factor | Univariable OR | 95% CI | \( p \)-Value | Multivariable OR | 95% CI | \( p \)-Value |
|----------------------------|---------------|--------|---------------|-----------------|--------|---------------|
| **Sex**                    |               |        |               |                 |        |               |
| Male          | Ref. level   | 1.98   | 1.4–2.8       | 0.0001          | Ref. level | 1.62       | 1.12–2.35    | 0.0109         |
| Female         | Ref. level   | 0.83   | 0.63–1.09     | 0.1875          | Ref. level | 2.07       | 1.06–4.06    | 0.0338         |
| **Age at diagnosis, ≥55 years** |               |        |               |                 |        |               |
| No            | Ref. level   | 3.88   | 2.14–7.04     | <0.0001         | Ref. level | 2.07       | 1.06–4.06    | 0.0338         |
| Yes           | Ref. level   | 1.88   | 1.43–2.47     | <0.0001         | Ref. level | 1.56       | 1.16–2.08    | 0.0028         |
| **Tumor diameter, >40 mm** |               |        |               |                 |        |               |
| No            | Ref. level   | 2.74   | 2.03–3.69     | <0.0001         | Ref. level | 1.9        | 1.38–2.63    | 0.0001         |
| Yes           | Ref. level   | 7.28   | 3.26–16.28    | <0.0001         | Ref. level | 3.33       | 1.37–8.14    | 0.0082         |
| **Multifocality** |               |        |               |                 |        |               |
| No            | Ref. level   | 4.05   | 2.5–6.56      | <0.0001         | Ref. level | 1.83       | 1.06–3.15    | 0.0292         |
| Yes           | Ref. level   | 4.07   | 3.5–5.53      | <0.0001         | Ref. level | 2.69       | 1.91–3.77    | <0.0001        |
| **Extrathyroidal extension** |               |        |               |                 |        |               |
| 0, no         | Ref. level   | 3.97   | 2.98–5.28     | <0.0001         | Ref. level | 1.9        | 1.38–2.63    | 0.0001         |
| 1. minor      | Ref. level   | 22.9   | 12.84–40.83   | <0.0001         | Ref. level | 3.33       | 1.37–8.14    | 0.0082         |
| 2. gross      | Ref. level   | 22.9   | 12.84–40.83   | <0.0001         | Ref. level | 3.33       | 1.37–8.14    | 0.0082         |
| **Angioinvasion** |               |        |               |                 |        |               |
| No            | Ref. level   | 1.88   | 1.43–2.47     | <0.0001         | Ref. level | 1.56       | 1.16–2.08    | 0.0028         |
| Yes           | Ref. level   | 1.88   | 1.43–2.47     | <0.0001         | Ref. level | 1.56       | 1.16–2.08    | 0.0028         |
| **Nodal metastases** |               |        |               |                 |        |               |
| No            | Ref. level   | 1.88   | 1.43–2.47     | <0.0001         | Ref. level | 1.56       | 1.16–2.08    | 0.0028         |
| Yes           | Ref. level   | 1.88   | 1.43–2.47     | <0.0001         | Ref. level | 1.56       | 1.16–2.08    | 0.0028         |
| **Distant metastases** |               |        |               |                 |        |               |
| No            | Ref. level   | 1.88   | 1.43–2.47     | <0.0001         | Ref. level | 1.56       | 1.16–2.08    | 0.0028         |
| Yes           | Ref. level   | 1.88   | 1.43–2.47     | <0.0001         | Ref. level | 1.56       | 1.16–2.08    | 0.0028         |
| **ATA initial risk** |               |        |               |                 |        |               |
| 0, low        | Ref. level   | 3.97   | 2.98–5.28     | <0.0001         | Ref. level | 1.9        | 1.38–2.63    | 0.0001         |
| 1. intermediate| Ref. level   | 3.97   | 2.98–5.28     | <0.0001         | Ref. level | 1.9        | 1.38–2.63    | 0.0001         |
| 2. high       | Ref. level   | 3.97   | 2.98–5.28     | <0.0001         | Ref. level | 1.9        | 1.38–2.63    | 0.0001         |

OR, odds ratio; CI, confidence interval; NA(0 in cell), not calculable (zero in cell); ATA, American Thyroid Association. *, variables with an asterisk were entered in a multivariable model.

Table 6. Final follow-up results according to sex.

| Final Follow-Up, n (%) | Total (n = 1547) | Female (n = 1358) | Male (n = 189) | \( p \)-Value |
|------------------------|------------------|-------------------|---------------|---------------|
| NED                    | 1423 (93.3%)     | 1264 (93.1%)      | 159 (84.1%)   | < 0.0001      |
| Non-NED                | 124 (6.7%)       | 94 (6.1%)         | 30 (15.9%)    |               |

NED, no evidence of disease.

As a summary for this research, we made an attempt to modify the ATA stratification system. Male sex was added to the prognosis worsening factors that qualify for non-low risk. Then, the sensitivity and specificity of modified and unmodified systems were compared. Such modification improves sensitivity of the stratification system (68.8% vs. 62.5%, \( p < 0.0001 \)) but also significantly worsens its specificity (75.2% vs. 67.6%, \( p < 0.0001 \)). Data are presented in Table 8.

Table 7. Effect of clinicopathological factors on non-NED in follow-up.

| Clinicopathological Factor | Univariable OR | 95% CI | \( p \)-Value | Multivariable OR | 95% CI | \( p \)-Value |
|----------------------------|---------------|--------|---------------|-----------------|--------|---------------|
| **Sex**                    |               |        |               |                 |        |               |
| Male          | Ref. level   | 2.54   | 1.63–3.95     | <0.0001         | Ref. level | 1.96       | 1.21–3.17    | 0.0062         |
| Female         | Ref. level   | 1.05   | 0.72–1.54     | 0.7918          | Ref. level | 1.05       | 0.72–1.54    | 0.7918         |
| **Age at diagnosis, ≥55 years** |               |        |               |                 |        |               |
| No            | Ref. level   | 3.86   | 1.91–7.81     | 0.0002          | Ref. level | 1.63       | 0.72–3.67    | 0.24           |
| Yes           | Ref. level   | 3.86   | 1.91–7.81     | 0.0002          | Ref. level | 1.63       | 0.72–3.67    | 0.24           |
| **Tumor diameter, >40 mm** |               |        |               |                 |        |               |
| No            | Ref. level   | 1.69   | 1.15–2.48     | 0.0077          | Ref. level | 1.69       | 0.82–1.9     | 0.3036         |
| Yes           | Ref. level   | 1.69   | 1.15–2.48     | 0.0077          | Ref. level | 1.69       | 0.82–1.9     | 0.3036         |
Table 7. Cont.

| Clinicopathological Factor | Univariable OR | 95% CI | p-Value | Multivariable OR | 95% CI | p-Value |
|----------------------------|----------------|--------|---------|-----------------|--------|---------|
| Extrathyroidal extension * |                |        |         |                 |        |         |
| 0. no Ref. level           |                |        |         |                 |        |         |
| 1. minor                   | 2.82           | 1.88–4.24 | <0.0001 | 1.72            | 1.1–2.71 | 0.0185 |
| 2. gross                   | 8.94           | 3.32–20.91 | <0.0001 | 2.98            | 1.07–8.32 | 0.0366 |
| Angioinvasion *            |                |        |         |                 |        |         |
| No Ref. level              | 4.68           | 2.67–8.19 | <0.0001 | 1.66            | 0.87–3.19 | 0.1272 |
| Yes Ref. level             | 4.68           | 2.67–8.19 | <0.0001 | 1.66            | 0.87–3.19 | 0.1272 |
| Nodal metastases *         |                |        |         |                 |        |         |
| No Ref. level              | 6.11           | 4.14–9.01 | <0.0001 | 3.89            | 2.5–6.03 | <0.0001 |
| Yes Ref. level             | 6.11           | 4.14–9.01 | <0.0001 | 3.89            | 2.5–6.03 | <0.0001 |
| Distant metastases *       |                |        |         |                 |        |         |
| No Ref. level              | 7.99           | 2.88–22.83 | 0.0001 | 3.18            | 0.93–10.94 | 0.0659 |
| Yes Ref. level             | 7.99           | 2.88–22.83 | 0.0001 | 3.18            | 0.93–10.94 | 0.0659 |
| ATA initial risk           |                |        |         |                 |        |         |
| 0. low Ref. level          | 4.76           | 3.12–7.27 | <0.0001 |                 |        |         |
| 1. intermediate            | 4.76           | 3.12–7.27 | <0.0001 |                 |        |         |
| 2. high                    | 16.11          | 8.83–29.38 | <0.0001 |                 |        |         |

NED, no evidence of disease; OR, odds ratio; CI, confidence interval; ATA, American Thyroid Association. * variables with an asterisk were entered in a multivariable model.

Table 8. Comparison of sensitivity and specificity between modified and unmodified ATA systems.

|                      | Unmodified ATA System | Modified ATA System | p-Value |
|----------------------|-----------------------|---------------------|---------|
| Sensitivity          | 62.5%                 | 68.8%               | <0.0001 |
| Specificity          | 75.2%                 | 67.6%               | <0.0001 |

ATA, American Thyroid Association.

4. Discussion

The results of this study show that males with PTC are more likely to present with some unfavorable clinicopathological risk factors such as lymph node metastases and angioinvasion. Liu et al. made similar observations [19]. However, we classified nodal metastases as N1 in a smaller percentage of patients than Liu et al.: 23.8% of males and 13.2% of females versus 29.1% and 19.3%, respectively. Moreover, Liu et al. found that men are more often diagnosed with a larger primary tumor [19]: mean tumor size (22.48 ± 21.79 mm for men vs. 16.93 ± 17.75 mm for women). However, we found this not to be the case (median tumor size: 8.0 mm for women and 8.0 mm for men in our study). Over 80% of our patients (85.9%) were diagnosed with a primary tumor smaller than 20 mm, although a tumor diameter larger than 40 mm was significantly more common in men.

Our findings indicate no differences between the sexes with respect to age at diagnosis. This disagrees with the results of two large studies based on U.S. and Chinese populations [19,20]. The median age of male and female patients was very similar between these studies: age at diagnosis was 49 years for women and 53 years for men. In our study, the median age for women was 50 years, and that for men was 51 years.

We also found that angioinvasion was significantly more common in male patients. However, its effect, particularly in males has not been described yet. Angioinvasion is thought to predict an increased risk of recurrence and poor prognosis, with treatment implications [21]. What is more, in accordance with the ATA Management Guidelines criteria, invasion of blood vessels is a crucial feature that has to be absent in the low-risk PTC.

The aim of the present study was to evaluate whether male sex is associated with worse course and prognosis of PTC. By the term “worse prognosis”, we mean a response to initial therapy that is other than excellent; this is because PTC-related death, although not frequent, usually affects patients with an incomplete response to initial treatment. This is in agreement with the study by Sapuppo et al. [22], who stated that patients not cured after initial therapy are at increased risk of persistent disease and a worse outcome. We identified minor extrathyroidal extensions, multifocality, angioinvasion, and distant and nodal metastases as factors that significantly increase the risk of a non-excellent response to treatment. This was confirmed by multivariate analysis.
Therefore, we assessed the effect of male sex on achieving a non-excellent response to initial therapy. Univariate analysis identified male sex as being associated with a non-excellent response to initial treatment, which was confirmed by multivariate analysis. Mendoza et al. identified male sex, along with the extent of the disease, multifocality, and lymph node metastasis, as factors that increase the risk of an incomplete response [23]. Nevertheless, multivariate analysis in the cited study did not include distant metastasis and angioinvasion. In our study, angioinvasion was a significantly relevant factor contributing to non-excellent response (OR, 1.83) [23]. The Sapuppo study indicated that male sex has an impact on persistent disease status (OR, 1.7), but they did not identify distant metastasis and angioinvasion as contributing factors, which might be the reason for the inconsistencies in the results [22].

By “worse course”, we mean the presence of persistent disease (described in this study as non-NED at the final follow-up). Multivariable analysis suggested that patients diagnosed with extrathyroidal extension (both minor and gross) and nodal metastases were at risk of non-NED at the final clinical assessment.

Univariate analysis of PTC patients identified male sex as a factor that may increase the probability of a non-NED diagnosis at the final clinical assessment. Such dependency was confirmed by multivariate analysis.

We also examined the frequency of disease recurrence. Recurrence was defined as the appearance of disease visualized in imaging studies and/or an increase in expression of tumor markers after a period of NED (as defined by ATA). It was observed in nineteen patients with PTC.

Chow [24] and Toniato [25] found that the risk of recurrence was increased by many factors, including age at diagnosis, tumor size, and nodal and distant metastases. In both cited studies, the follow-up period was longer than that in our study: Toniato et al. [25] used an average follow-up period of 7.8 years, whereas that used by Chow et al. [24] was 8.4 years. The frequency of recurrence may differ between studies because they use different definitions. For example, in a multicenter study by Zahedi et al. each of the co-authors defined recurrence of disease differently and did not specify the disease-free term. Hence, some patients with persistent disease were included in the recurrence group [26]. In our study, recurrence was defined as a relapse of disease in patients who achieved an excellent response to therapy after the NED period. It was a very rare phenomenon, seen only in nineteen of our patients. It was not possible to assess statistical significance of sex impact on recurrence because in our cohort cancer recurrences were observed only in females.

We also reported no PTC-related deaths; therefore, we could not examine the effect of sex on death.

Analysis of other studies conducted in European and American populations indicated that male sex is not associated with higher mortality (cancer-related death) [6,20,25,27,28]. Some adverse clinicopathological features (assessed immediately after surgery) were more common in men. Sex affects the clinical final status of disease (NED vs. non-NED). This is in line with the findings of Tuttle et al., Kowalska et al., Momesso et al. and Castagna et al. [14,16,29,30], who showed that the delayed risk stratification system based on response to initial therapy correlated more strongly with final status of disease (NED/non-NED) than the early stratification systems created by the ATA. In our study, male sex was a factor that predicted a worse response to initial therapy, and there was a relationship between sex and final status of disease.

Authors of many previous studies have attempted to verify that the current stratification system is reliable and effectively predicts the prognosis for patients after initial DTC treatment [14,31,32]. In some studies, value of new markers for stratification was examined. For example, Vuong et al. and Moon et al. found the correlation between concomitant BRAF and TERT promoter mutations with more aggressive disease course [33,34]. This finding was included in Clinical Practice Guidelines by the European Society for Medi-
cal Oncology and added as a high risk of persistent/recurrent disease predictor in PTC patients [35].

In our research, we tried to modify the ATA stratification system by adding male sex to the high-risk predictors. Although such modification improves the sensitivity of the test (68.8% vs. 62.5%), it does not enhance its specificity. Further studies on larger groups of patients should be carried out to assess whether males require treatment modalities or oncological follow-up protocols that are different from those of females as our results in this matter are inconclusive.

Our study has some limitations. First, the number of patients with advanced clinical disease was small, although almost all patients with PTC treated in our center from 2000 to 2018 were included. Second, the follow-up period was short. Follow-up for more than 6 years may reveal more information about recurrence or death related to PTC.

5. Conclusions

Male sex is associated with some unfavorable clinicopathological characteristics of PTC and contributes to a worse response to initial therapy or final disease status. Thus, further studies on larger groups of patients should be carried out to assess whether males require treatment modalities or oncological follow-up protocols that are different from those of females.

Author Contributions: Conceptualization: A.G., A.C., K.F., A.S. (Alicja Skuza), and A.K. (Aldona Kowalska); Data curation: A.G., A.C., K.F., A.S. (Alicja Skuza), and M.C.; Formal analysis: M.C.; Investigation: A.G., A.C., K.F., A.S. (Alicja Skuza), D.G.-P., A.W., T.T., E.M., M.S., K.G.-J., J.J., P.O., A.K. (Artur Kuchareczko), A.S. (Agnieszka Suligowska), M.C., S.G., and A.K. (Aldona Kowalska); Methodology: M.C.; Software, M.C.; Validation: A.G., A.C., K.F., A.S. (Alicja Skuza), and A.K. (Aldona Kowalska); Resources: A.G., A.C., K.F., A.S. (Alicja Skuza), D.G.-P., A.W., T.T., E.M., M.S., K.G.-J., J.J., P.O., A.K. (Artur Kuchareczko), A.S. (Agnieszka Suligowska), M.C., S.G., and A.K. (Aldona Kowalska); Visualization: A.G., A.C., K.F., and A.S. (Alicja Skuza); Supervision: A.K. (Aldona Kowalska); Funding acquisition: A.K. (Aldona Kowalska); Writing—original draft: A.G., A.C., K.F., A.S. (Alicja Skuza), and A.K. (Aldona Kowalska); Writing—review and editing: A.G., A.C., K.F., A.S. (Alicja Skuza), D.G.-P., A.W., T.T., E.M., M.S., K.G.-J., J.J., P.O., A.K. (Artur Kuchareczko), A.S. (Agnieszka Suligowska), M.C., S.G., and A.K. (Aldona Kowalska). All authors have read and agreed to the published version of the manuscript.

Funding: The project was financed under the Regional Initiative of Excellence program of the Minister of Science and Higher Education (project no. 024/RID/2018/19; amount of financing: 11,999,000 zł).

Institutional Review Board Statement: The study plan was accepted by the Bioethics Committee at Jan Kochanowski University in Kielce, Poland (Number-7/2020).

Informed Consent Statement: Written informed consent was not required because the data were obtained retrospectively.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to their containing information that could compromise the privacy of research participants.

Conflicts of Interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

References

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef]
2. Schonfeld, S.J.; Neta, G.; Sturgis, E.M.; Pfeiffer, R.M.; Hutchinson, A.A.; Xu, L.; Wheeler, W.; Guénel, P.; Rajaraman, P.; de Vathaire, F.; et al. Common Genetic Variants in Sex Hormone Pathway Genes and Papillary Thyroid Cancer Risk. Thyroid 2012, 22, 151–156. [CrossRef] [PubMed]
3. Kim, J.; Gosnell, J.E.; Roman, S.A. Geographic influences in the global rise of thyroid cancer. Nat. Rev. Endocrinol. 2020, 16, 17–29. [CrossRef] [PubMed]
28. Husson, O.; Haak, H.R.; van Steenbergen, L.N.; Nieuwlaat, W.-A.; van Dijk, B.A.C.; Nieuwenhuijzen, G.A.P.; Karim-Kos, H.; Kuijpers, J.L.; Van De Poll-Franse, L.V.; Coebergh, J.W.W. Rising incidence, no change in survival and decreasing mortality from thyroid cancer in The Netherlands since 1989. *Endocr. Relat. Cancer* **2013**, *20*, 263–271. [CrossRef] [PubMed]

29. Momesso, D.P.; Vaisman, F.; Yang, S.P.; Bulzico, D.A.; Corbo, R.; Vaisman, M.; Tuttle, R.M. Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine. *J. Clin. Endocrinol. Metab.* **2016**, *101*, 2692–2700. [CrossRef] [PubMed]

30. Castagna, M.G.; Maino, F.; Cipri, C.; Belardini, V.; Theodoropoulou, A.; Cevenini, G.; Pacini, F. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. *Eur. J. Endocrinol.* **2011**, *165*, 441–446. [CrossRef]

31. Ruben, R.; Pavithran, P.V.; Menon, V.U.; Nair, V.; Kumar, H. Performance of ATA Risk Stratification Systems, Response to Therapy, and Outcome in an Indian Cohort of Differentiated Thyroid Carcinoma Patients: A Retrospective Study. *Eur. Thyroid J.* **2019**, *8*, 312–318. [CrossRef]

32. Pandya, A.; Caoili, E.M.; Jawad-Makki, F.; Wasnik, A.P.; Shankar, P.R.; Bude, R.; Haymart, M.R.; Davenport, M.S. Limitations of the 2015 ATA Guidelines for Prediction of Thyroid Cancer: A Review of 1947 Consecutive Aspirations. *J. Clin. Endocrinol. Metab.* **2018**, *103*, 3496–3502. [CrossRef] [PubMed]

33. Vuong, H.G.; Altibi, A.M.A.; Duong, U.N.P.; Hassell, L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta-analysis. *Clin. Endocrinol.* **2017**, *87*, 411–417. [CrossRef] [PubMed]

34. Moon, S.; Song, Y.S.; Kim, Y.A.; Lim, J.A.; Cho, S.W.; Moon, J.H.; Hahn, S.; Park, D.; Park, Y. Effects of Coexistent BRAF V600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis. *Thyroid* **2017**, *27*, 651–660. [CrossRef] [PubMed]

35. Filetti, S.; Durante, C.; Hartl, D.; Leboulleux, S.; Locati, L.D.; Newbold, K.; Papotti, M.G.; Berruti, A.; on behalf of the ESMO Guidelines Committee. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **2019**, *30*, 1856–1883. [CrossRef] [PubMed]